Downloadable fact sheet answering the most common question TheSocialMedwork asked by healthcare providers.
Resources
-
March 13, 2019
-
February 28, 2019
Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years.
-
February 28, 2019
In recognition of Rare Disease Day, our colleague, Sera, shares her story of her dad's fight with Multiple System Atrophy (MSA).
-
February 27, 2019
-
February 25, 2019
A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.
-
February 07, 2019
The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).
-
February 07, 2019
CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).
-
February 05, 2019
Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.
-
February 05, 2019
Teresa's husband was diagnosed with ALS. She spent 11 years as his caregiver and discusses her experiences.
-
January 30, 2019
Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).
-
January 30, 2019
After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.
-
January 25, 2019
Realistic new year's resolutions for lasting results!
-
January 18, 2019
Over 50 countries have approved Spinraza (nusinersen), but not all have made it available to the patients who need it.
-
January 14, 2019
New medicine shows statistically significant improvements for prostate cancer patients.
-
January 08, 2019
We are looking for an outstanding Web Developer to be responsible for the coding, innovative design and layout of our website.
-
December 20, 2018
A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.
-
December 18, 2018
Our team shares their take on what we do at TheSocialMedwork.
-
December 17, 2018
Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.
-
December 14, 2018
Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).
-
December 03, 2018
Australia provides reimbursement for cystic fibrosis medicine.
-
November 30, 2018
The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.
-
November 29, 2018
A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
-
November 29, 2018
In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).
-
November 21, 2018
Doctors hold the key to access new medicines.
-
November 14, 2018
How we find and ship medicines on behalf of patients.
-
October 21, 2018
-
October 03, 2018
-
October 03, 2018
-
October 03, 2018
-
September 17, 2018
How two professors imagine a better world for stakeholders in the medical industry.